Latest Insider Transactions at Ultragenyx Pharmaceutical Inc. (RARE)
This section provides a real-time view of insider transactions for Ultragenyx Pharmaceutical Inc. (RARE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Ultragenyx Pharmaceutical Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Ultragenyx Pharmaceutical Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,162
-2.05%
|
$814,854
$67.37 P/Share
|
|
Mar 01
2022
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+22.6%
|
-
|
|
Mar 01
2022
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,821
-7.67%
|
$186,186
$66.62 P/Share
|
|
Mar 01
2022
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+5.79%
|
-
|
|
Mar 01
2022
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
2,374
-1.1%
|
$156,684
$66.62 P/Share
|
|
Mar 01
2022
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+26.13%
|
-
|
|
Mar 01
2022
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,886
-10.18%
|
$190,476
$66.62 P/Share
|
|
Mar 01
2022
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.53%
|
-
|
|
Mar 01
2022
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
3,234
-8.06%
|
$213,444
$66.62 P/Share
|
|
Mar 01
2022
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,710
+17.87%
|
-
|
|
Mar 01
2022
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
843
-5.99%
|
$55,638
$66.62 P/Share
|
|
Mar 01
2022
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+19.11%
|
-
|
|
Mar 01
2022
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
4,498
-9.04%
|
$296,868
$66.62 P/Share
|
|
Mar 01
2022
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+27.82%
|
-
|
|
Mar 01
2022
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,713
-10.84%
|
$179,058
$66.62 P/Share
|
|
Mar 01
2022
|
Mardi Dier CFO & Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.14%
|
-
|
|
Mar 01
2022
|
Mardi Dier CFO & Executive Vice President |
SELL
Open market or private sale
|
Direct |
534
-1.38%
|
$35,244
$66.62 P/Share
|
|
Jan 30
2022
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,657
-4.31%
|
$109,362
$66.3 P/Share
|
|
Oct 14
2021
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
358
-0.71%
|
$28,998
$81.14 P/Share
|
|
Oct 14
2021
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
853
-0.14%
|
$69,093
$81.0 P/Share
|
|
Oct 14
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
310
-1.08%
|
$25,110
$81.14 P/Share
|
|
Oct 14
2021
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
286
-0.13%
|
$23,166
$81.14 P/Share
|
|
Oct 14
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
140
-0.99%
|
$11,340
$81.14 P/Share
|
|
Oct 14
2021
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
358
-0.88%
|
$28,998
$81.14 P/Share
|
|
Oct 14
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
303
-1.2%
|
$24,543
$81.14 P/Share
|
|
Oct 14
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
359
-0.93%
|
$29,079
$81.14 P/Share
|
|
Oct 14
2021
|
Mardi Dier CFO & Executive Vice President |
SELL
Open market or private sale
|
Direct |
3,261
-7.76%
|
$264,141
$81.16 P/Share
|
|
Oct 12
2021
|
Mardi Dier CFO & Executive Vice President |
SELL
Open market or private sale
|
Direct |
3,477
-7.64%
|
$285,114
$82.79 P/Share
|
|
Sep 30
2021
|
Thomas Richard Kassberg CBO & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
109,734
+33.63%
|
$0
$0.31 P/Share
|
|
Sep 13
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
819
-5.45%
|
-
|
|
Sep 08
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,336
-20.38%
|
$733,600
$100.65 P/Share
|
|
Sep 08
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,336
+16.93%
|
$396,144
$54.5 P/Share
|
|
Sep 02
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-6.06%
|
$250,000
$100.18 P/Share
|
|
Sep 02
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+5.71%
|
$137,500
$55.0 P/Share
|
|
Sep 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-6.06%
|
$250,000
$100.03 P/Share
|
|
Sep 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+5.71%
|
$137,500
$55.0 P/Share
|
|
Jul 06
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
375
-1.46%
|
$34,125
$91.53 P/Share
|
|
Jun 29
2021
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
3,895
+50.0%
|
-
|
|
Jun 24
2021
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+21.8%
|
-
|
|
Jun 24
2021
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.93%
|
-
|
|
Jun 24
2021
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.02%
|
-
|
|
Jun 24
2021
|
Lars Ekman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.93%
|
-
|
|
Jun 24
2021
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+14.58%
|
-
|
|
Jun 24
2021
|
William Aliski Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+3.11%
|
-
|
|
Jun 24
2021
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.93%
|
-
|
|
Jun 21
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
572
-2.18%
|
$53,768
$94.96 P/Share
|
|
Jun 19
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
437
-1.64%
|
$41,078
$94.63 P/Share
|
|
Jun 10
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,329
-4.43%
|
$132,900
$100.0 P/Share
|
|
May 07
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
393
-1.45%
|
$44,409
$113.67 P/Share
|
|
May 06
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
364
-0.93%
|
$41,132
$113.67 P/Share
|